CPRX
Catalyst Pharmaceuticals Inc
31.50$
+0.0%
vs. previous close
Closing price · As of: Jul 21, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 99.8% | 99.7% | 99.4% | 99.8% | 91.3% | 99.1% | 82.8% | 88.4% | 85.4% | 46.7% | 73.2% | 80.8% | |
| 20.7% | 47.0% | 33.3% | 67.3% | 27.4% | 79.7% | 67.7% | 72.1% | 79.4% | 29.3% | 60.8% | 64.1% | |
| 89.4% | 97.2% | 96.9% | 98.4% | 88.5% | 84.1% | 72.9% | 80.4% | 79.4% | 29.3% | 60.8% | 64.1% | |
| 8.0% | – | – | – | – | 9.4% | 3.1% | 2.8% | 2.9% | 11.4% | 7.7% | 11.6% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 1.7% | 2.4% | 3.3% | 1.8% | 3.3% | 2.3% | 3.4% | |
| 0.2% | 0.3% | 0.6% | 0.2% | 0.4% | 0.2% | 0.1% | 1.7% | 0.2% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | 8.6% | 41.3% | 18.4% | 11.9% | |
| 19.7% | 7.7% | 5.7% | 5.2% | 16.0% | 22.0% | 11.8% | 13.0% | 20.0% | 17.5% | 14.5% | 13.8% | |
| 13.3% | 5.7% | 5.0% | 5.0% | 15.7% | 21.4% | 11.8% | 11.4% | 15.3% | 16.2% | 14.2% | 13.3% | |
| – | – | – | – | – | 0.3% | 0.0% | 0.1% | 0.1% | 0.1% | 0.0% | 0.0% | |
| 4.1% | 3.0% | 2.2% | 2.3% | 3.9% | 3.7% | 2.2% | 1.2% | 1.1% | 3.1% | 1.9% | 1.0% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 80.3% | 92.3% | 94.3% | 94.8% | 84.0% | 78.0% | 88.2% | 87.0% | 80.0% | 82.5% | 85.5% | 86.2% | |
| -159.1% | -149.9% | -259.3% | -148.2% | -265.6% | -114.5% | -27.9% | -11.1% | 13.3% | 25.8% | 33.5% | 42.8% | |
| 146.1% | 134.5% | 198.7% | 100.5% | 169.8% | 94.3% | 55.2% | 45.3% | 29.7% | 24.2% | 14.7% | 11.5% |
Data as of: July 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.